Juan Martin-Liberal
Overview
Explore the profile of Juan Martin-Liberal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
883
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gonzalez-Cao M, Puertolas T, Luis Manzano J, Maldonado C, Yelamos O, Berciano-Guerrero M, et al.
Clin Transl Oncol
. 2024 May;
26(10):2572-2583.
PMID: 38750345
Background: The development of highly active drugs has improved the survival of melanoma patients, but elevated drug prices place a significant burden on health care systems. In Spain, the public...
12.
DAlise A, Leoni G, Cotugno G, Siani L, Vitale R, Ruzza V, et al.
Clin Cancer Res
. 2024 Mar;
30(11):2412-2423.
PMID: 38506710
Purpose: Personalized vaccines targeting multiple neoantigens (nAgs) are a promising strategy for eliciting a diversified antitumor T-cell response to overcome tumor heterogeneity. NOUS-PEV is a vector-based personalized vaccine, expressing 60...
13.
Drakaki A, Powles T, Bamias A, Martin-Liberal J, Shin S, Friedlander T, et al.
Clin Cancer Res
. 2023 Aug;
29(21):4373-4384.
PMID: 37651261
Purpose: The MORPHEUS platform was designed to identify early efficacy signals and evaluate the safety of novel immunotherapy combinations across cancer types. The phase Ib/II MORPHEUS-UC trial (NCT03869190) is evaluating...
14.
Soto-Castillo J, Llavata-Marti L, Fort-Culillas R, Andreu-Cobo P, Moreno R, Codony C, et al.
Int J Mol Sci
. 2023 Jul;
24(13).
PMID: 37446319
The SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin-remodeling complex is one of the most remarkably altered epigenetic regulators in cancer. Pathogenic mutations in genes encoding SWI/SNF-related proteins have been recently described in many...
15.
Manzano J, Martin-Liberal J, Fernandez-Morales L, Benitez G, Medina Martinez J, Quindos M, et al.
Melanoma Res
. 2023 Mar;
33(5):388-397.
PMID: 36988401
BRAF and MEK inhibitor, dabrafenib plus trametinib, adjuvant therapy is effective for high-risk resected melanoma patients with BRAF - V600 mutations. However, real-world evidence is limited. We aimed to determine...
16.
Desai J, Fong P, Moreno V, Frentzas S, Meniawy T, Markman B, et al.
Br J Cancer
. 2023 Feb;
128(8):1418-1428.
PMID: 36797356
Background: Many patients do not respond or eventually relapse on treatment with programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoint inhibitors due to secondary or acquired resistance; therefore, there...
17.
Lozano-Rabella M, Garcia-Garijo A, Palomero J, Yuste-Estevanez A, Erhard F, Farriol-Duran R, et al.
Clin Cancer Res
. 2023 Feb;
29(12):2250-2265.
PMID: 36749875
Purpose: Tumor antigens are central to antitumor immunity. Recent evidence suggests that peptides from noncanonical (nonC) aberrantly translated proteins can be presented on HLA-I by tumor cells. Here, we investigated...
18.
Marco C, Simo M, Alemany M, Casasnovas C, Dominguez R, Vilarino N, et al.
J Clin Med
. 2023 Jan;
12(1).
PMID: 36614930
Immunotherapy with immune checkpoint inhibitors (ICIs) have been reported to induce de novo or exacerbate pre-existing Myasthenia Gravis (MG). We present a single center case series of patients who developed...
19.
Gonzalez-Cao M, Puertolas T, Martinez-Vila C, Carrera C, Maldonado Seral C, Rodriguez-Jimenez P, et al.
Clin Transl Oncol
. 2022 Dec;
25(3):768-775.
PMID: 36566266
Background: The Spanish Melanoma Group (GEM) developed a national registry of patients with melanoma infected by SARS-CoV-2 ("GRAVID"). Methods: The main objective was to describe the COVID-19 fatality rate in...
20.
Davis E, Martin-Liberal J, Kristeleit R, Cho D, Blagden S, Berthold D, et al.
J Immunother Cancer
. 2022 Oct;
10(10).
PMID: 36316061
Background: OX40 is a costimulatory receptor upregulated on antigen-activated T cells and constitutively expressed on regulatory T cells (Tregs). INCAGN01949, a fully human immunoglobulin G1κ anti-OX40 agonist monoclonal antibody, was...